QTTB.US Q32 Bio Inc

Healthcare Biotechnology USA Stocks
8.63 USD
Close of Nov 18, 2026
1.91 23.57
Market cap
USD 258M
P/E
2.3x
P/B
0.86x
ROE
-11.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is QTTB.US undervalued?

Graham number

The Graham number of Q32 Bio Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Q32 Bio Inc fundamental analysis

No fundamental analysis for Q32 Bio Inc yet.

Q32 Bio Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Q32 Bio Inc

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling me…

Full company profile